Incidence of narcotic abuse during pregnancy in northwestern Ontario: Three-year prospective cohort study

Canadian Family Physician

Volumn 60, Issue 10, 2014, Pages e493-e498

  Kelly, Len ^a   Guilfoyle, John ^a   Dooley, Joe ^a   Antone, Irwin ^a   Gerber Finn, Lianne ^b   Dooley, Roisin ^b   Brunton, Nicole ^c   Kakegamuck, Kara ^d   Muileboom, Jill ^c   Hopman, Wilma ^e   Cromarty, Helen ^f   Linkewich, Barb ^f   Maki, Jennifer ^f  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Sioux Lookout Meno Ya Win Health Centre   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f Quality and Clinical Support Services SLMHC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; MORPHINE; NARCOTIC AGENT; OPIATE; OXYCODONE; TETRAHYDROCANNABINOL;

ADULT; ARTICLE; BIRTH; CANADA; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; FEMALE; FIRST NATION; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NARCOTIC DEPENDENCE; NEWBORN; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PROSPECTIVE STUDY; URINALYSIS; WITHDRAWAL SYNDROME; YOUNG ADULT; AMERICAN INDIAN; ETHNOLOGY; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; SUBSTANCE-RELATED DISORDERS;

ADULT; FEMALE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; ONTARIO; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 84908003738     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bell S. Cat Lake chief pleads for drug abuse help. Wawatay News Online 2012 Feb 2. Available from: www.wawataynews.ca/archive/all/2012/2/2/cat-lake-chief-pleads-drug-abuse-help-22346. Accessed 2013 Aug 31.
2. Garrick R. Shibogama addresses prescription drug abuse. Wawatay News Online 2012 Dec 20. Available from: www.wawataynews.ca/archive/all/2012/12/20/shibogama-addresses-prescription-drug-abuse-23892. Accessed 2013 Aug 21.
3. Kelly L, Dooley J, Cromarty H., Minty B, Morgan A, Madden S., et al. Narcotic-exposed neonates in a First Nations population in northwestern Ontario. Incidence and implications. Can Fam Physician 2011;57:e441-7. Available from: www.cfp.ca/content/57/11/e441.full. pdf+html. Accessed 2014 Sep 4.
4. Kelly L, Minty B, Madden S., Dooley J, Antone I. The occasional management of narcotic exposure in neonates. Can J Rural Med 2011;16(3):98-101.
5. Kaltenbach K, Holbrook AM, Coyle M.G., Heil SH, Salisbury AL, Stine SM, et al Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 2012;107(SUPPL. 1):45-52.
6. Purdue Pharma Canada [website]. Purdue Pharma Canada statement on generic OxyContin. Pickering, ON: Purdue Pharma Canada; 2012. Available from: www.purdue.ca/en/media-room/archives#2012. Accessed 2013 Aug 31.
7. Health Canada [website]. Updates to the Drug Benefit List - fall-winter 2012. Ottawa, ON: Health Canada; 2012. Available from: www.hc-sc.gc.ca/fniah-spnia/pubs/nihb-ssna/-drug-med/2012-additions-winter-ajouts-hiver/index-eng.php. Accessed 2013 Aug 31.
8. Ontario Drug Benefit Program. Important reminder regarding the funding status of oxycodone controlled release tablet - OxyNEO. Toronto, ON: Ministry of Health and Long-Term Care; 2012. Available from: www.health.gov.on.ca/en/pro/programs/drugs/opdp-eo/notices/exec-office-odb-20121004.pdf. Accessed 2013 Aug 31.
9. Dhalla IA, Mamdani MM, Sivilotti M.L., Kopp A., Qureshi O Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181(12):891-6. Epub 2009 Dec 7.
10. Neonatal Abstinence Work Group. Neonatal abstinence syndrome (NAS) clinical practice guidelines. Toronto, ON: Provincial Council for Maternal and Child Health; 2012. Available from: http://pcmch.on.ca/publications-resources/clinical-practice-guidelines. Accessed 2014 Sep 4.
11. Dow K, Ordean A, Murphy-Oikonen J, Pereira J., Koren G, Roukema H, et al Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 2012;19(3):e488-506. Epub 2012 Nov 23.
12. Minozzi S, Amato L, Bellisario C., Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013;(12):CD006318.
13. Fischer G, Jagsch R, Eder H., Gombas W, Etzersdorfer P, Schmidl-Mohl K, et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999;94(2):231-9.
14. Walker R, Cromarty H, Kelly L., St Pierre Hansen N. Achieving cultural safety in Aboriginal health services: implementation of a cross-cultural safety model in a hospital setting. Divers Health Care 2009;6(1):11-22.
15. Baewert A, Jagsch R, Winklbaur B., Kaiser G, Thau K, Unger A., et al. Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics. Eur Addict Res 2012;18(3):130-9. Epub 2012 Feb 21.
16. Jones HE, Kaltenbach K, Heil S.H., Stine SM, Coyle MG, Arria AM, et al Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363(24):2320-31.
17. Kiepek N, Hancock L, Toppozini D., Cromarty H, Morgan A, Kelly L. Facilitating medical withdrawal from opiates in rural Ontario. Rural Remote Health 2012;12:2193. Epub 2012 Oct 23.
18. Katt M, Chase C, Samokhvalov A.V., Argento E., Rehm J, Fischer B. Feasibility and outcomes of a community-based taper-to-low-dose-maintenance suboxone treatment program for prescription opioid dependence in a remote First Nations community in northern Ontario. J Aborig Health 2012;9(1):52-9.